Pharmacovigilance – News and Features

Data indicate short courses of low-dose immunosuppression may be sufficient to prevent immune rejection of GRNOPC1.

Scientists at Buck Institute discovered that longevity was increased in the worms when the lithium turned down the activity of a gene that modulates the basic structure of chromosomes.

As part of the feasibility agreement, NMT will apply its proprietary technology High Gravity Controlled Precipitation to the design of drug particles for pulmonary inhalation.

Schizophrenia may occur, in part, because of a problem in an intermittent on/off switch for a gene involved in making a key chemical messenger in the brain.

A group of Israeli scientists have recently identified genes responsible for the positive response of many multiple sclerosis patients to the drug Copaxone®.

The study results provide insight into the development biology and suggest new ways to treat atherosclerosis and cancer.

MHI’s research project based on a mixed academic/private partnership in pharmacogenomics has been selected for the new PRIVAC competition launched by Genome Quebec.

A report from National Research Council recommends development of genomic technologies for identifying toxic chemicals and understanding individual vulnerabilities.

Early clinical data supporting use of Aastrom Bone Repair Cells (BRCs) in treatment of osteonecrosis of the femoral head also presented.

Newly formed nonprofit corporation unites industry, academia and government in first large-scale study of genetics and drug safety.